Dapagliflozin 10 MG

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

SGLT2 Inhibition in Hemodialysis

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

Comparative Effectiveness of Dapagliflozin, Metformin, and Lifestyle Modification for Antipsychotic-Induced Weight Gain: An Open-Label Pragmatic Trial

Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Dapagliflozin After Transcatheter Aortic Valve Implantation

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

DAPAgliflozin for Renal Protection in Heart Transplant Recipients

Efficacy and Safety of Dapagliflozin in Acute Heart Failure

SGLT2 Inhibition in Older Obese Adults With Pre-diabetes

DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk